Rxivist logo

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

By Weina Sun, Stephen McCroskery, Wen-Chun Liu, Sarah R. Leist, Yonghong Liu, Randy A. Albrecht, Stefan Slamanig, Justine Oliva, Fatima Amanat, Alexandra Schäfer, Kenneth H. Dinnon, Bruce L. Innis, Adolfo Garcia-Sastre, Florian Krammer, Ralph S. Baric, Peter Palese

Posted 31 Jul 2020
bioRxiv DOI: 10.1101/2020.07.30.229120

A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,410 times
  • Download rankings, all-time:
    • Site-wide: 10,213 out of 118,977
    • In microbiology: 553 out of 9,394
  • Year to date:
    • Site-wide: 4,042 out of 118,977
  • Since beginning of last month:
    • Site-wide: 3,893 out of 118,977

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News